Roccuzzo Gabriele, Macagno Nicole, Giordano Silvia, Fava Paolo, Quaglino Pietro
Department of Medical Sciences, Dermatology Clinic, University of Turin.
Dermatol Reports. 2025 Feb 6;17(1). doi: 10.4081/dr.2024.10002. Epub 2024 Oct 2.
Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL) that typically presents in the early phase as inflammatory erythematous patches or plaques, with epidermotropism as the histopathological hallmark of the disease. Traditionally, in the early stages, non-aggressive options represent the first-line strategy: topical corticosteroids, phototherapy, radiotherapy, and occasionally adopting a "wait-and-see" approach for minimally symptomatic patients. In patients with advanced or recurrent disease, good results can be achieved with immune modifiers, chemotherapeutic agents, total skin irradiation, or extracorporeal photochemotherapy, and maintenance therapy is often required. The past decade has seen an expansion of therapies that can be used in this setting by increasing new therapeutic strategies. The key advancements coming from recently published trials are resumed in this article.
蕈样肉芽肿（MF）是最常见的皮肤T细胞淋巴瘤（CTCL），其早期通常表现为炎症性红斑斑块，表皮内亲润是该疾病的组织病理学标志。传统上，在疾病早期，非侵袭性治疗方案是一线策略：外用糖皮质激素、光疗、放疗，对于症状轻微的患者偶尔采用“观察等待”的方法。对于晚期或复发性疾病患者，免疫调节剂、化疗药物、全身皮肤照射或体外光化学疗法可取得良好效果，且通常需要维持治疗。在过去十年中，通过增加新的治疗策略，可用于该疾病的治疗方法有所扩展。本文总结了近期发表的试验所取得的关键进展。
